Home
Clinical Resources Search
PQI: Abiraterone acetate (Yonsa®) Patient Selection and Management

Abiraterone acetate (Yonsa®) Patient Selection and Management

Download PQI pdf

Last Updated: December 6, 2024

By: Jeffrey Pasucal, PharmD, CSP

About this PQI

The purpose of this PQI is to discuss the clinical considerations around the use of abiraterone acetate fine particle formulation (Yonsa®) to optimize outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI